November 15th, 2023 | Tübingen, Germany
Press Release
Capnopharm is the winner of the GERMAN MEDICAL AWARD 2023
Capnopharm is the winner of the German Medical Award 2023. Our company was recognized as the most innovative medical Start-Up in Germany amongst 800 contestants. This victory confirms Capnopharm’s leadership and highlights PIPAC’s disruptive power at the crossroads of pharma, engineering, and peritoneal medicine.
Prof. Marc Reymond, MD MBA, and Ranjita Sahoo, PhD, received the prize in person at an award ceremony held in Dusseldorf, Germany, on 15th November 2023, in the presence of Karl-Josef Laumann, Minister for Labor, Health and Social Affairs.
Concentrating on patient-oriented care, The German Medical Award is the leading and only medicine and medical management award in Germany, Austria and Switzerland. This award acknowledges outstanding performance and innovations in medicine with a focus on interdisciplinary, medical, technical, and pharmaceutical care solutions.
ABOUT CAPNOPHARM
Capnopharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC® (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC® provides numerous avenues for research and development in oncology – from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
Contact :
S. Laurent, VP Global Sales & Business Development, s.laurent@capnopharm.com
PIPAC® and Capnopen® are registered Trademarks of Capnopharm GmbH, Tübingen, Germany.
Tübingen, July 1st, 2022
Press Release
Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.
Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.
“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improve quality of life with minimal morbidity 1. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA 2. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.
“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Dr. Marc A. Reymond, MD MBA, Capnopharm’s CEO.
About Capnopharm
Disclaimer
07/06/2022
Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
On June 4 th 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Prof. Somashekhar from Manipal Comprehensive Cancer Center, Bangalore, India, presented interim results of a randomized control trial comparing Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy (IV) in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer:
These results show that PIPAC is safe and feasible for women with unresectable platinum-resistant ovarian cancer. PIPAC showed better objective response rates and improved quality of life when compared to the chemotherapy arm, with acceptable morbidity.
The primary endpoint was the objective response rate, assessed with RECIST 1.1 between PIPAC and IV chemotherapy arm. Secondary endpoints evaluated the two groups’ quality of life (QLQ C-30) and morbidity (CTCAE 4.0 and Clavien dindo). PIPAC was done with a dose of cisplatin of 15 mg /m2 and doxorubicin of 3 mg/m2. The choice of IV chemotherapy was at the discretion of the treating physician.
Forty patients underwent 105 PIPAC applications, with nearly 25 (62.5%) completing three cycles. Forty patients underwent IV chemotherapy same time, with nearly 23 (57.5%) having received at least five cycles. Mean age 57.3±8.05, PCI 24.45±6.39, with nearly 45.5% of patients had previous surgery and 72.5% of patients having received at least two lines of prior chemotherapy, and nearly 60% having ascites. The objective response rate is 66.6% versus 22.5%, grade 3-4 events were 10.0% vs. 35.7% in PIPAC and IV arm respectively. Histological regression was seen in 67.5% of patients with three cycles of PIPAC. Functional, symptom and global health scores at day 120 were significantly better with the PIPAC arm when compared to the IV arm.
This study is a milestone in delivering high-level medical evidence for the efficacy and excellent tolerability of PIPAC for treating peritoneal metastasis.
Reference:
https://meetings.asco.org/abstracts-presentations/207828, consulted on June 7th , 2022
June 20th, 2023 | Tübingen, Germany
Press Release
Capnopharm GmbH awarded with the BSFZ innovation seal of German Federal Ministry of Education and Research.
Capnopharm is proud to announce that the company has been awarded today with the seal of the Certification Body for Research Grants (BSFZ). BSFZ is part of the German Federal Ministry of Education and Research. The BFSZ seal is awarded exclusively to small and medium enterprises (SME) that are entitled to claim funding from research grants, after a thorough independent audit. The BSFZ seal confirms that Capnopharm’s R&D projects are original, novel and attractive. Although Capnopharm projects are ambitious, they have been considered by the experts to be budgetable, systematic, transferable, and reproducible.
Dr. Ranjita Sahoo, Capnopharm’s Chief Scientific Officer, is delighted about this recognition: “Capnopharm was a Winner of the German Innovation Award in 2022. The BSFZ seal is further proof of Capnopharm’s innovation potential. This seal will ease Capnopharm`s access to national and international innovation grants in the future.” Stéphane Laurent, Capnopharm’s Vice President for Global Sales & Business Development, adds: “Capnopharm is recognized as a pioneer of loco-regional drug delivery as aerosols worldwide. Our R&D pipeline, including new devices and drug-device combinations, will strengthen this leadership, fuel our revenue streams and enable Capnopharm’s access to a large and emerging PIPAC market”.
ABOUT CAPNOPHARM
Capnopharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC® (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC® provides numerous avenues for research and development in oncology – from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
Contact :
S. Laurent, VP Global Sales & Business Development, s.laurent@capnopharm.com
PIPAC® and Capnopen® are registered Trademarks of Capnopharm GmbH, Tübingen, Germany.
Tübingen, July 1st, 2022
Press Release
Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.
Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.
“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improve quality of life with minimal morbidity 1. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA 2. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.
“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Dr. Marc A. Reymond, MD MBA, Capnopharm’s CEO.
About Capnopharm
Disclaimer
07/06/2022
Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
On June 4 th 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Prof. Somashekhar from Manipal Comprehensive Cancer Center, Bangalore, India, presented interim results of a randomized control trial comparing Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy (IV) in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer:
These results show that PIPAC is safe and feasible for women with unresectable platinum-resistant ovarian cancer. PIPAC showed better objective response rates and improved quality of life when compared to the chemotherapy arm, with acceptable morbidity.
The primary endpoint was the objective response rate, assessed with RECIST 1.1 between PIPAC and IV chemotherapy arm. Secondary endpoints evaluated the two groups’ quality of life (QLQ C-30) and morbidity (CTCAE 4.0 and Clavien dindo). PIPAC was done with a dose of cisplatin of 15 mg /m2 and doxorubicin of 3 mg/m2. The choice of IV chemotherapy was at the discretion of the treating physician.
Forty patients underwent 105 PIPAC applications, with nearly 25 (62.5%) completing three cycles. Forty patients underwent IV chemotherapy same time, with nearly 23 (57.5%) having received at least five cycles. Mean age 57.3±8.05, PCI 24.45±6.39, with nearly 45.5% of patients had previous surgery and 72.5% of patients having received at least two lines of prior chemotherapy, and nearly 60% having ascites. The objective response rate is 66.6% versus 22.5%, grade 3-4 events were 10.0% vs. 35.7% in PIPAC and IV arm respectively. Histological regression was seen in 67.5% of patients with three cycles of PIPAC. Functional, symptom and global health scores at day 120 were significantly better with the PIPAC arm when compared to the IV arm.
This study is a milestone in delivering high-level medical evidence for the efficacy and excellent tolerability of PIPAC for treating peritoneal metastasis.
Reference:
https://meetings.asco.org/abstracts-presentations/207828, consulted on June 7th , 2022
June 12th, 2023 | Tübingen, Germany
Press Release
Capnopharm GmbH is pleased to announce that the company has received certification of its quality system to the ISO 13485:2016 standard. This ISO certification documents that the company’s quality management system adheres to the most current regulatory requirements specific to the medical device industry. This International Standard, through the implementation of a quality management system, complements the technical requirements for a product to ensure its safety, regulatory compliance, and performance.
“We are proud of receiving this certification recognizing the commitment of our team to quality, and to the highest customer’s and international regulatory expectations”, said Dr. Kristijana Milovic-Holm, Head of Quality Management and Regulatory Affairs at Capnopharm. “We are dedicated to continuously improving the quality of our products, processes, and services to ensure patient safety and to meet future market access requirements”.
Prof. Marc Reymond, Capnopharm`s CEO, adds: “At Capnopharm, we strive to achieve the highest standards in terms of innovation and quality. The ISO 13485:2016 certification is a collective achievement of all of our employees. We want to send a clear message to patients and physicians, positioning our company as a trustworthy and reliable supplier”.
The ISO 13485:2016 standard is based on ISO 9001:2008 and specifies the requirements an organization needs to demonstrate in providing one or more stages of the life-cycle of a medical device, which includes the design, development, production, storage, distribution, installation, and servicing of a medical device.
ABOUT CAPNOPHARM
Capnopharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC® (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC® provides numerous avenues for research and development in oncology – from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
Contact :
S. Laurent, VP Global Sales & Business Development, s.laurent@capnopharm.com
PIPAC® and Capnopen® are registered Trademarks of Capnopharm GmbH, Tübingen, Germany.
Tübingen, July 1st, 2022
Press Release
Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.
Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.
“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improve quality of life with minimal morbidity 1. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA 2. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.
“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Dr. Marc A. Reymond, MD MBA, Capnopharm’s CEO.
About Capnopharm
Disclaimer
07/06/2022
Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
On June 4 th 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Prof. Somashekhar from Manipal Comprehensive Cancer Center, Bangalore, India, presented interim results of a randomized control trial comparing Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy (IV) in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer:
These results show that PIPAC is safe and feasible for women with unresectable platinum-resistant ovarian cancer. PIPAC showed better objective response rates and improved quality of life when compared to the chemotherapy arm, with acceptable morbidity.
The primary endpoint was the objective response rate, assessed with RECIST 1.1 between PIPAC and IV chemotherapy arm. Secondary endpoints evaluated the two groups’ quality of life (QLQ C-30) and morbidity (CTCAE 4.0 and Clavien dindo). PIPAC was done with a dose of cisplatin of 15 mg /m2 and doxorubicin of 3 mg/m2. The choice of IV chemotherapy was at the discretion of the treating physician.
Forty patients underwent 105 PIPAC applications, with nearly 25 (62.5%) completing three cycles. Forty patients underwent IV chemotherapy same time, with nearly 23 (57.5%) having received at least five cycles. Mean age 57.3±8.05, PCI 24.45±6.39, with nearly 45.5% of patients had previous surgery and 72.5% of patients having received at least two lines of prior chemotherapy, and nearly 60% having ascites. The objective response rate is 66.6% versus 22.5%, grade 3-4 events were 10.0% vs. 35.7% in PIPAC and IV arm respectively. Histological regression was seen in 67.5% of patients with three cycles of PIPAC. Functional, symptom and global health scores at day 120 were significantly better with the PIPAC arm when compared to the IV arm.
This study is a milestone in delivering high-level medical evidence for the efficacy and excellent tolerability of PIPAC for treating peritoneal metastasis.
Reference:
https://meetings.asco.org/abstracts-presentations/207828, consulted on June 7th , 2022
Press Release
Capnopharm is proud to announce that its new CapnoPen® CP-001k received CE certification (MDR) for aerosolizing chemotherapy, DNA, RNA, nanomolecules, viruses, and immunotherapy into body cavities. As the only nebulizer with such certification, the new CapnoPen® is setting a new regulatory standard in Intraperitoneal Chemotherapy.
Stéphane Rohan Laurent, Capnopharm’s VP Sales & Business Development, comments: “Receiving CE certification constitutes a landmark achievement for our new CapnoPen® technology. It also responds to the growing demand from the oncology community for durable, harmonized standards in Intraperitoneal Chemotherapy.”
Capnopharm’s new CapnoPen® is the first PIPAC® nebulizer to obtain CE marking under the new MDR regulation 2017/745. Prof. Marc Reymond, Capnopharm`s CEO, sees here a benefit for the patients and their physicians: “Capnopharm`s new Capnopen® is approved for its effective intended use, namely aerosolizing chemotherapy, DNA, RNA, nanomolecules, viruses, and immunotherapy into body cavities. This is in contrast to other nebulizers on the market which are only approved for aerosolizing aqueous solutions or for irrigating the abdominal cavity: in clinical practice, these nebulizers are used “off-label”. The new Capnopen® is now classified into the appropriate risk category. Its regulatory approval meets the most current MDR standards and is the result of a thorough technical, biological, and clinical evaluation. This evaluation and the resulting approval protect the interests of patients and healthcare practitioners alike”.
ABOUT CAPNOPHARM
Capnopharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC® (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC® provides numerous avenues for research and development in oncology – from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
Contact :
S. Laurent, VP Global Sales & Business Development, s.laurent@capnopharm.com
PIPAC® and Capnopen® are registered Trademarks of Capnopharm GmbH, Tübingen, Germany.
Tübingen, July 1st, 2022
Press Release
Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.
Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.
“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improve quality of life with minimal morbidity 1. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA 2. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.
“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Dr. Marc A. Reymond, MD MBA, Capnopharm’s CEO.
About Capnopharm
Disclaimer
07/06/2022
Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
On June 4 th 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Prof. Somashekhar from Manipal Comprehensive Cancer Center, Bangalore, India, presented interim results of a randomized control trial comparing Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy (IV) in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer:
These results show that PIPAC is safe and feasible for women with unresectable platinum-resistant ovarian cancer. PIPAC showed better objective response rates and improved quality of life when compared to the chemotherapy arm, with acceptable morbidity.
The primary endpoint was the objective response rate, assessed with RECIST 1.1 between PIPAC and IV chemotherapy arm. Secondary endpoints evaluated the two groups’ quality of life (QLQ C-30) and morbidity (CTCAE 4.0 and Clavien dindo). PIPAC was done with a dose of cisplatin of 15 mg /m2 and doxorubicin of 3 mg/m2. The choice of IV chemotherapy was at the discretion of the treating physician.
Forty patients underwent 105 PIPAC applications, with nearly 25 (62.5%) completing three cycles. Forty patients underwent IV chemotherapy same time, with nearly 23 (57.5%) having received at least five cycles. Mean age 57.3±8.05, PCI 24.45±6.39, with nearly 45.5% of patients had previous surgery and 72.5% of patients having received at least two lines of prior chemotherapy, and nearly 60% having ascites. The objective response rate is 66.6% versus 22.5%, grade 3-4 events were 10.0% vs. 35.7% in PIPAC and IV arm respectively. Histological regression was seen in 67.5% of patients with three cycles of PIPAC. Functional, symptom and global health scores at day 120 were significantly better with the PIPAC arm when compared to the IV arm.
This study is a milestone in delivering high-level medical evidence for the efficacy and excellent tolerability of PIPAC for treating peritoneal metastasis.
Reference:
https://meetings.asco.org/abstracts-presentations/207828, consulted on June 7th , 2022
August 18th, 2022
Press Release
Capnopharm is proud to announce its selection as Finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation – Capnodrug® – in the Health Entrepreneur Award category. CapnoPharm was shortlisted out of a pool of 800 applicants, including some of the world’s leading pharmaceutical companies, and is eagerly awaiting the awards ceremony in London on 17th November 2022.
Each year, over one million patients worldwide are diagnosed with peritoneal cancer – a condition often consecutive to stomach, bowel or gynecological cancer. For most patients, there is no truly effective therapy. Systemic chemotherapy is less effective than in other indications. There is no chemotherapeutic drug approved for intraperitoneal drug delivery.
The awarded CapnoDrug® technology is a patented drug delivery platform with several benefits against peritoneal cancer : homogenous distribution of the drug within the abdominal cavity, direct access to the tumor site, sustained drug release and enhanced delivery to the tumor cells. CapnoDrug® can also be used for non-viral and viral gene delivery.
In May 2022, Capnopharm was already an acclaimed winner of the German Innovation Awards in the Medical Technologies Category. Reaching the finals of the Pharma Europe Award 2022 marks the sixth award achievement for CapnoPharm and its sister company Capnomed since 2020.
Capnopharm is committed to advancing peritoneal cancer care and improving the health and well-being of patients around the world – for the greatest possible quality of life.
For more on Pharma Awards Europe 2022 please visit.
https://events.reutersevents.com/pharma/awards-europe.
Please visit www.capnopharm.com
Contact : S. Laurent, VP Global Sales & Business Development, s.laurent@capnopharm.com
Tübingen, July 1st, 2022
Press Release
Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.
Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.
“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improve quality of life with minimal morbidity 1. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA 2. “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms “, adds Dr. Sahoo.
“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Dr. Marc A. Reymond, MD MBA, Capnopharm’s CEO.
About Capnopharm
Disclaimer
07/06/2022
Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
On June 4 th 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Prof. Somashekhar from Manipal Comprehensive Cancer Center, Bangalore, India, presented interim results of a randomized control trial comparing Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy (IV) in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer:
These results show that PIPAC is safe and feasible for women with unresectable platinum-resistant ovarian cancer. PIPAC showed better objective response rates and improved quality of life when compared to the chemotherapy arm, with acceptable morbidity.
The primary endpoint was the objective response rate, assessed with RECIST 1.1 between PIPAC and IV chemotherapy arm. Secondary endpoints evaluated the two groups’ quality of life (QLQ C-30) and morbidity (CTCAE 4.0 and Clavien dindo). PIPAC was done with a dose of cisplatin of 15 mg /m2 and doxorubicin of 3 mg/m2. The choice of IV chemotherapy was at the discretion of the treating physician.
Forty patients underwent 105 PIPAC applications, with nearly 25 (62.5%) completing three cycles. Forty patients underwent IV chemotherapy same time, with nearly 23 (57.5%) having received at least five cycles. Mean age 57.3±8.05, PCI 24.45±6.39, with nearly 45.5% of patients had previous surgery and 72.5% of patients having received at least two lines of prior chemotherapy, and nearly 60% having ascites. The objective response rate is 66.6% versus 22.5%, grade 3-4 events were 10.0% vs. 35.7% in PIPAC and IV arm respectively. Histological regression was seen in 67.5% of patients with three cycles of PIPAC. Functional, symptom and global health scores at day 120 were significantly better with the PIPAC arm when compared to the IV arm.
This study is a milestone in delivering high-level medical evidence for the efficacy and excellent tolerability of PIPAC for treating peritoneal metastasis.
Reference:
https://meetings.asco.org/abstracts-presentations/207828, consulted on June 7th , 2022